Mixed: narrative review drawing on human, animal and cell research ยท Narrative review
Li W et al., Current Issues in Molecular Biology, 2025
A 2025 narrative (non-systematic) review of the vitiligo treatment pipeline, from an author group independent of the landmark, situates the baricitinib+NB-UVB trial among JAK-inhibitor studies. Its prose accurately states the week-36 VASI result (-44.8% vs -9.2% for placebo), that this did not surpass the prespecified 42.9% threshold, and that the between-group difference came from a post hoc analysis; however the review's clinical-trials table mislabels the same trial. The review frames combination therapy as, in its words, 'likely to remain the most promising approach' and lists tissue-resident memory (TRM) and regulatory T-cell targeting among emerging directions.
Source: Li W, Dong P, Zhang G, Hu J, Yang S. Emerging Therapeutic Innovations for Vitiligo Treatment. Current Issues in Molecular Biology. 2025;47(3):191.
Verified research card EL-LM-T04-01-d-R1